HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Thomas J Herzog Selected Research

Topotecan (Hycamtin)

3/2011A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).
12/2008Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
5/2008Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
1/2007Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
11/2006Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
10/2006CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
11/2004Recurrent ovarian cancer: how important is it to treat to disease progression?
7/2004The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
9/2003Workshop: options for therapy in ovarian cancer.
9/2003Clinical experience with topotecan in relapsed ovarian cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Thomas J Herzog Research Topics

Disease

59Neoplasms (Cancer)
09/2015 - 03/2002
42Ovarian Neoplasms (Ovarian Cancer)
06/2015 - 01/2002
19Endometrial Neoplasms (Endometrial Cancer)
09/2015 - 06/2002
13Carcinoma (Carcinomatosis)
07/2013 - 01/2002
7Neoplasm Metastasis (Metastasis)
06/2015 - 06/2003
5Ascites
06/2015 - 01/2002
5Thrombocytopenia (Thrombopenia)
10/2014 - 01/2002
4Hypertension (High Blood Pressure)
10/2014 - 11/2004
4Neutropenia
10/2014 - 01/2002
4Microsatellite Instability
06/2004 - 06/2002
3Hemorrhage
07/2014 - 11/2002
3Wounds and Injuries (Trauma)
10/2013 - 06/2010
3Venous Thromboembolism
11/2011 - 06/2010
3Sarcoma (Soft Tissue Sarcoma)
07/2008 - 12/2004
2Female Genital Diseases
05/2014 - 02/2013
2Pelvic Organ Prolapse
08/2013 - 11/2012
2Adenocarcinoma
01/2012 - 12/2007
2Carcinosarcoma
11/2010 - 11/2008
2Clear Cell Adenocarcinoma
01/2009 - 12/2004
2Infection
07/2005 - 11/2004
2Hemolytic-Uremic Syndrome
04/2005 - 11/2004
2Anemia
11/2004 - 01/2002
1Endometrioid Carcinoma
09/2015
1Diarrhea
10/2014
1Fatigue
10/2014
1Proteinuria
07/2014
1Abscess
10/2013
1Peritonitis
10/2013
1Endometriosis (Adenomyosis)
08/2013
1Leiomyoma (Uterine Fibroids)
08/2013
1Breast Neoplasms (Breast Cancer)
07/2013
1Thymoma (Thymic Carcinoma)
07/2013
1Placenta Accreta
07/2011
1Hypersensitivity (Allergy)
06/2011
1Adenosarcoma
11/2010
1Mucositis
07/2010
1Vascular System Injuries
06/2010
1Postoperative Hemorrhage
06/2010

Drug/Important Bio-Agent (IBA)

11PlatinumIBA
10/2014 - 01/2002
11Topotecan (Hycamtin)FDA LinkGeneric
03/2011 - 01/2002
8Paclitaxel (Taxol)FDA LinkGeneric
05/2014 - 01/2002
7pegylated liposomal doxorubicinIBA
10/2012 - 09/2003
6Carboplatin (JM8)FDA LinkGeneric
05/2014 - 01/2004
61-dodecylpyridoxal (PLD)IBA
10/2012 - 04/2005
4taxaneIBA
10/2014 - 08/2006
4gemcitabineFDA Link
03/2010 - 01/2004
4Deoxyglucose (2 Deoxy D glucose)IBA
12/2005 - 06/2003
4N-methylsuccinimideIBA
06/2004 - 06/2002
3Biological Markers (Surrogate Marker)IBA
09/2015 - 10/2010
3docetaxel (Taxotere)FDA Link
03/2014 - 08/2003
3trabectedin (ecteinascidin 743)IBA
10/2012 - 07/2010
3VaccinesIBA
05/2008 - 09/2003
3DNA (Deoxyribonucleic Acid)IBA
12/2007 - 06/2002
3Cisplatin (Platino)FDA LinkGeneric
11/2007 - 07/2004
2Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2015 - 02/2013
2HormonesIBA
08/2014 - 06/2010
2bevacizumabFDA Link
05/2014 - 03/2014
2Sirolimus (Rapamycin)FDA Link
07/2013 - 02/2013
2Phosphotransferases (Kinase)IBA
07/2013 - 02/2013
2Carbon MonoxideIBA
11/2010 - 07/2005
2Doxorubicin (Adriamycin)FDA LinkGeneric
11/2004 - 01/2002
2Etoposide (VP 16)FDA LinkGeneric
11/2004 - 11/2004
2Type I DNA Topoisomerases (Topoisomerase I)IBA
07/2004 - 01/2002
1Progesterone Receptors (Progesterone Receptor)IBA
09/2015
1Estrogens (Estrogen)FDA Link
09/2015
1Naphazoline (Clear, All)FDA LinkGeneric
08/2015
1Vascular Endothelial Growth FactorsIBA
06/2015
1Angiogenesis InhibitorsIBA
06/2015
1catumaxomabIBA
11/2014
1pazopanibIBA
10/2014
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2014
1oxaliplatin (Eloxatin)FDA LinkGeneric
03/2014
1Proteins (Proteins, Gene)IBA
01/2014
1Carboxymethylcellulose Sodium (Polycell)FDA Link
10/2013
1MAP Kinase Kinase 1IBA
07/2013
1sorafenib (BAY 43-9006)FDA Link
07/2013
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
07/2013
1Amyloid Precursor Protein Secretases (beta-Secretase)IBA
03/2013
1Folate Receptor 1IBA
02/2013
1Epidermal Growth Factor Receptor (EGF Receptor)IBA
02/2013
1Insulin (Novolin)FDA Link
02/2013
1TOR Serine-Threonine KinasesIBA
02/2013
1paclitaxel poliglumex (XYOTAX)IBA
06/2011
1Glutamic Acid (Glutamate)FDA Link
06/2011
1Adenosarcoma of the uterusIBA
11/2010

Therapy/Procedure

26Hysterectomy
05/2014 - 08/2004
20Drug Therapy (Chemotherapy)
09/2015 - 01/2002
8Lymph Node Excision (Lymph Node Dissection)
01/2013 - 04/2002
4Ovariectomy (Oophorectomy)
10/2010 - 04/2002
4Laparotomy
11/2004 - 03/2004
3Brachytherapy
08/2014 - 12/2011
3Radiotherapy
05/2010 - 01/2005
3Adjuvant Radiotherapy
04/2009 - 10/2003
2Therapeutics
01/2014 - 01/2010
2Aftercare (After-Treatment)
01/2007 - 11/2004
2Catheters
05/2006 - 01/2002
1Hormone Replacement Therapy (Therapy, Hormone Replacement)
08/2014
1Colectomy
10/2013
1Surgical Mesh
11/2012
1Gynecologic Surgical Procedures (Gynecologic Surgery)
11/2011